Speech Title: Early Clinical Evaluation of HT-6184 a Potent, Selective, Orally Bioavailable, Allosteric Inhibitor of Nek7/NLRP3
Biography: Jared Bearss co-founded Halia Therapeutics in 2017. His prior industry experience includes co-founding Wasatch Scientific and managing the genomic biology department and projects for Code Nutrition. Jared also has experience working in the academic field of life sciences and was Sr. Research Analyst, and Lab Manager at the Huntsman Cancer Institute.
Jared’s experience in both industry and academic sectors of the life sciences
field provided him with many areas of expertise including genomics, cell
biology, cell culture, western blotting, and molecular biology. His scientific
background and entrepreneurial spirit got him interested in scaling
pharmaceutical startups and managing technical and organizational aspects of
company development.
Jared has a Bachelor of Science in neuropsychology/neurophysiology from Utah
Valley University and is an MBA Business Executive from the David Eccles School
of Business at the University of Utah.